Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
Nirsevimab, a monoclonal antibody with an extended half-life, is designed to protect infants from respiratory syncytial virus disease after a single intramuscular dose. This placebo-controlled trial involving 1447 preterm infants at 164 sites in 23 countries assessed the effectiveness of nirsevimab...
Saved in:
| Published in: | The New England journal of medicine Vol. 383; no. 5; pp. 415 - 425 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Massachusetts Medical Society
30.07.2020
|
| Subjects: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!